Aileron Therapeutics is a biopharmaceutical
company developing and advancing a revolutionary class of drugs called Stapled
Peptides. The company's proprietary Stapled Peptides platform is a breakthrough
approach to creating drugs for highly sought after biological targets using its
novel peptide stabilizing technologies. Aileron's Stapled Peptides have
demonstrated their unique ability to penetrate cells throughout the body and
modulate intracellular and extracellular protein-protein interactions, critical
control points for most human diseases. The ability to target and regulate
these control points affords the unique opportunity to exploit potentially
thousands of well characterized, yet currently "undruggable" cellular
targets with applications in all human diseases. The Aileron technology works
by locking peptides into their biologically active shape, mimicking the
structures found in nature, and ultimately endows the peptide with unique and
beneficial drug-like properties, including efficient cell penetration, high affinity
binding to large target protein surfaces, specificity, and excellent stability
within the body.
Other investors include: Apple Tree Partners,
Excel Venture Management, Novartis Venture Fund, Roche Ventures, and SR One.